Business Description
Cell Source Inc
NAICS : 325413
SIC : 2834
ISIN : US15114L1044
Description
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -64.64 | |||||
| Debt-to-Equity | -0.59 | |||||
| Debt-to-EBITDA | -2.18 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.5 | |||||
| 3-Year EPS without NRI Growth Rate | -0.8 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -18.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.16 | |||||
| 9-Day RSI | 17.9 | |||||
| 14-Day RSI | 26.43 | |||||
| 6-1 Month Momentum % | -16.67 | |||||
| 12-1 Month Momentum % | 166566.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | |||||
| Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10 | |||||
| Shareholder Yield % | -29368.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.18 | |||||
| EV-to-EBITDA | -2.18 | |||||
| EV-to-FCF | -4.04 | |||||
| Earnings Yield (Greenblatt) % | -45.87 | |||||
| FCF Yield % | -29362.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLCS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cell Source Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.17 | ||
| Beta | -267.3 | ||
| Volatility % | 22107.56 | ||
| 14-Day RSI | 26.43 | ||
| 14-Day ATR ($) | 0.072182 | ||
| 20-Day SMA ($) | 0.32676 | ||
| 12-1 Month Momentum % | 166566.67 | ||
| 52-Week Range ($) | 0.0002 - 0.74 | ||
| Shares Outstanding (Mil) | 38.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cell Source Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cell Source Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cell Source Inc Frequently Asked Questions
What is Cell Source Inc(CLCS)'s stock price today?
The current price of CLCS is $0.00. The 52 week high of CLCS is $0.74 and 52 week low is $0.00.
When is next earnings date of Cell Source Inc(CLCS)?
The next earnings date of Cell Source Inc(CLCS) is .
Does Cell Source Inc(CLCS) pay dividends? If so, how much?
Cell Source Inc(CLCS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers